Non-Current Assets

Equity Securities (FV-NI and No Readily Determinable FV)

Gilead Sciences Equity Securities (FV-NI and No Readily Determinable FV) decreased by 0.9% to $8.83B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.4%, from $8.14B to $8.83B. Over 2 years (FY 2023 to FY 2025), Equity Securities (FV-NI and No Readily Determinable FV) shows an upward trend with a 16.7% CAGR.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2023
Last reportedQ1 2026May 7, 2026
Metric ID: equity_securities_fvni_no_fv

Historical Data

10 periods
 Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$6.55B$4.04B$3.66B$5.89B$10.79B$8.14B$5.57B$8.34B$8.91B$8.83B
QoQ Change—-38.4%-9.4%+61.1%+83.1%-24.5%-31.7%+49.9%+6.8%-0.9%
YoY Change————+64.8%+101.8%+52.2%+41.6%-17.4%+8.4%
Range$3.66B – $10.79B
CAGR+14.2%
Avg YoY Growth+41.9%
Median YoY Growth+46.9%

Frequently Asked Questions

What is Gilead Sciences's equity securities (fv-ni and no readily determinable fv)?
Gilead Sciences (GILD) reported equity securities (fv-ni and no readily determinable fv) of $8.83B in Q1 2026.
How has Gilead Sciences's equity securities (fv-ni and no readily determinable fv) changed year-over-year?
Gilead Sciences's equity securities (fv-ni and no readily determinable fv) increased by 8.4% year-over-year, from $8.14B to $8.83B.
What is the long-term trend for Gilead Sciences's equity securities (fv-ni and no readily determinable fv)?
Over 2 years (2023 to 2025), Gilead Sciences's equity securities (fv-ni and no readily determinable fv) has grown at a 16.7% compound annual growth rate (CAGR), from $6.55B to $8.91B.